15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives.
Guilford Pharmaceuticals
Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries.
Guilford Pharmaceuticals
Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors.
Guilford Pharmaceuticals
Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones.
Guilford Pharmaceuticals
Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II.
Guilford Pharmaceuticals
Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.
Guilford Pharmaceuticals
Synthesis and biological evaluation of non-peptidic cyclophilin ligands.
Guilford Pharmaceuticals
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Guilford Pharmaceuticals
Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate. potent inhibitors of glutamate carboxypeptidase II.
Guilford Pharmaceuticals
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.
Guilford Pharmaceuticals
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Guilford Pharmaceuticals
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.
Guilford Pharmaceuticals
